Market Place
Sourcing Support
Sanofi And Regeneron Show Data For Dupixent In Hives After FDA Rejection
11 Sep 2024 //
FIERCE PHARMA
Kashiv Completes Phase III Enrollment For ADL018, XOLAIR Biosimilar
25 Jul 2024 //
BUSINESSWIRE
Kashiv Licenses Proposed XOLAIR Biosimilar To Amneal
01 Jul 2024 //
BUSINESSWIRE
Amneal Adds Omalizumab Biosimilar To Portfolio, Now Eight Products
01 Jul 2024 //
BUSINESSWIRE
Celltrion Healthcare`s Omlyclo (omalizumab) Receives Approval in the Europe
29 May 2024 //
EMA
EC approves Celltrion’s Omlyclo for allergic conditions
24 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Celltrion Omlyclo® Ec Approval: First Omalizumab Biosimilar In Europe
23 May 2024 //
BUSINESSWIRE
Celltrion USA completes submission of BLA to U.S. FDA for CT-P39
10 Mar 2024 //
PR NEWSWIRE
Roche`s Xolair reduces reactions to severe food allergies in study
25 Feb 2024 //
REUTERS
Xolair becomes first medicine approved in US for food allergy
17 Feb 2024 //
FDA
Genentech`s Biologic Xolair (omalizumab) Receives Approval in the U.S.
16 Feb 2024 //
FDA
Novartis Ends PIII Peanut Allergy Trial in Another Flop for Xolair Successor
19 Jan 2024 //
BIOSPACE
Genentech`s food allergy medication gets priority review nod from the FDA
20 Dec 2023 //
ENDPTS
FDA grants priority review to Xolair (omalizumab) for children
19 Dec 2023 //
GLOBENEWSWIRE
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018
02 Oct 2023 //
BUSINESSWIRE
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018
05 Jul 2023 //
BUSINESSWIRE
Genentech`s Biologic Xolair (Omalizumab) Receives Approval in the U.S.
17 Mar 2023 //
FDA
Genentech to start construction on a new manufacturing facility in California
11 Feb 2023 //
ENDPTS
Celldex offers a positive early readout for their rival drug
01 Jul 2022 //
ENDPTS
Sanofi`s Dupixent comes up short, stops hives trial
18 Feb 2022 //
FIERCEPHARMA
Launch of Generium’s Omalizumab Biosimilar Marks Selexis’ 9th Commercial Product
09 Feb 2022 //
BUSINESSWIRE
Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma
02 Feb 2022 //
BUSINESSWIRE
Novartis suffers shock setback as Xolair successor fails phase 3
21 Dec 2021 //
FIERCEBIOTECH
Novartis says ligelizumab suffers setback in late-stage studies
18 Dec 2021 //
METRO
Novartis data shows complete control of CSU, improves HRQoL: patients
30 Sep 2021 //
PHARMABIZ
Enforcement Report - Week of July 14, 2021
14 Jul 2021 //
FDA
Aiming to rebound from blunders years ago, Celldex touts a Phase Ib win
12 Jul 2021 //
ENDPTS
FDA Approvals Roundup: Trodelvy and Xolair
16 Apr 2021 //
RAPS
Novartis receives FDA approval of Xolair® (omalizumab) self-injection
13 Apr 2021 //
PRNESWIRE
Novartis gets breakthrough designation for Xolair successor
14 Jan 2021 //
ENDPTS
Roche`s Xolair gets US nod for nasal polyps treatment
02 Dec 2020 //
PHARMATIMES
FDA approves Xolair® (omalizumab) for adults with nasal polyps
01 Dec 2020 //
ROCHE
FDA accepts application for self-administered Xolair use
12 Aug 2020 //
PHARMATIMES
Novartis` Xolair scores European approval to treat chronic nasal polyps
05 Aug 2020 //
PHARMAFILE
Novartis receives positive CHMP opinion for new Xolair®
26 Jun 2020 //
PRESS RELEASE
Could Prozac help fight neuroblastoma?
09 Jan 2020 //
PHARMA TIME
Novartis abandons asthma drug after late-stage failure
16 Dec 2019 //
PHARMA TIMES
Novartis` Xolair follow-up banishes hives in 42% of patients with chronic hives
08 Oct 2019 //
FIERCE BIOETCH
Health Canada Issues Recall of Novartis Pharmaceuticals` Xolair (Omalizumab) Powder For Solution
11 Sep 2019 //
HEALTH CANADA
Catalent expands; Hospira and Novartis issue recalls
10 Sep 2019 //
FIERCE PHARMA
Genentech settles fight over cancer drug trade secrets with Taiwan`s JHL
06 Sep 2019 //
FIERCEPHARMA
Sanofi & Regeneron`s Dupixent scores 3rd FDA approval
27 Jun 2019 //
FIERCE PHARMA
As rivals crowd in, Can Novartis` Xolair remain a blockbuster?
04 Jun 2019 //
FIERCE PHARMA
Sanofi, Regeneron dive deep on asthma in debut digital awareness campaign
04 Jun 2019 //
FIERCE PHARMA
Genentech`s Xolair (Omalizumab) Receives Supplemental Approval in US
03 May 2019 //
FDA
Novartis plots to retain hives patients with monoclonal antibody that outshines Xolair
04 Dec 2018 //
ENDPTS
ICER On Asthma Biologics: 50%-79% Price Discounts Needed
15 Nov 2018 //
PHARMA INTEL
Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
04 Oct 2018 //
FIERCE PHARMA
Genentech vet Myrtle Potter takes a leading role in Vant ops
10 Jul 2018 //
ENDPTS
AZ writes off its second pivotal COPD trial for Fasenra, killing expansion plans
31 May 2018 //
ENDPTS
